On February 15, 2024 Curadev reported CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that distinguish it from agents that bind to STING’s cGAMP site (Press release, Curadev, FEB 15, 2024, View Source [SID1234640164]). An intravenous formulation of this lead asset (CRD3874-SI) recently received approval from the US FDA for use in first-in-human studies in patients with advanced solid cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pre-clinical studies presented by Curadev at the annual meeting of the Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) in San Diego, USA, in November 2023, showed that intravenous regimens of the drug caused robust immune-mediated tumor clearance in a range of tumor types in mice and that intravenous twice-weekly doses of CRD3874 as a single agent were well tolerated in monkeys. These features of CRD3874-SI predict a high therapeutic index in humans and support clinical investigation of this agent in cancer patients.
The poster was co-authored by Dr. Ciara Kelly, MD, Memorial Sloan Kettering Cancer Center, who is the PI for the FIH study (NCT06021626). Monali Banerjee, VP R&D at Curadev, who leads the STING programs and is the lead author of the poster, said, "CRD3874 is clearly unlike CDN-competitive STING agonists, since its distinct pharmacology and tolerability appear to be related to its allosteric binding mode. We are hopeful that the promising preclinical studies presented here will speak to the therapeutic potential of immune activation by CRD3874-SI in the context of advanced cancer in humans."